Ovarian cancer risk factor associations by primary anatomic site: The ovarian cancer cohort consortium

RT Fortner; MS Rice; SF Knutsen; MJ Orlich; K Visvanathan; AV Patel; MM Gaudet; A Tjønneland; M Kvaskoff; R Kaaks; A Trichopolou; V Pala; N Charlotte Onland-Moret; IT Gram; P Amiano; A Idahl; NE Allen; E Weiderpass; JN Poynter; K Robien; GG Giles; RL Milne; VW Setiawan; MA Merritt; PA Van Den Brandt; A Zeleniuch-Jacquotte; AA Arslan; KM O'Brien; DP Sandler; A Wolk; N Hakansson; HR Harris; B Trabert; N Wentzensen; SS Tworoger; LJ Schouten

Journal article

Ovarian cancer risk factor associations by primary anatomic site: The ovarian cancer cohort consortium

RT Fortner, MS Rice, SF Knutsen, MJ Orlich, K Visvanathan, AV Patel, MM Gaudet, A Tjønneland, M Kvaskoff, R Kaaks, A Trichopolou, V Pala, N Charlotte Onland-Moret, IT Gram, P Amiano, A Idahl, NE Allen, E Weiderpass, JN Poynter, K Robien Show all

Cancer Epidemiology Biomarkers and Prevention | AMER ASSOC CANCER RESEARCH | Published : 2020

DOI: 10.1158/1055-9965.EPI-20-0354

Abstract

Background: Epithelial ovarian, fallopian tube, and primary peritoneal cancers have shared developmental pathways. Few studies have prospectively examined heterogeneity in risk factor associations across these three anatomic sites. Methods: We identified 3,738 ovarian, 337 peritoneal, and 176 fallopian tube incident cancer cases in 891,731 women from 15 prospective cohorts in the Ovarian Cancer Cohort Consortium. Associations between 18 putative risk factors and risk of ovarian, peritoneal, and fallopian tube cancer, overall and for serous and high-grade serous tumors, were evaluated using competing risks Cox proportional hazards regression. Heterogeneity was assessed by likelihood ratio tes..

View full abstract

University of Melbourne Researchers

Graham Giles Author

Roger Milne Author

Related Projects (3)

Epidemiology of chronic disease, health interventions and DNA studies

PRECISION PUBLIC HEALTH FOR MAJOR CANCERS - NOVEL APPROACHES TO BUILDING THE GENETIC, EPIGENETIC AND LIFESTYLE KNOWLEDGE BASE FOR ASSESSING RISK AND PROGNOSIS

The Program of research seeks to increase our understanding of cancer risk. We will use our large collections of population and family-based..

THE HEALTH 2020 COHORT STUDY (HEALTH 2020)

Our aim is to develop appropriate infrastructures necessary to facilitate access by researchers to the accumulated data, including questionn..

Grants

Awarded by Office of Dietary Supplements

Funding Acknowledgements

Supported by Department of Defense Ovarian Cancer Research Program grant W81XWH-12-1-0561 (PI: to S.S. Tworger). Also supported by K05 CA154337 from the NCI and Office of Dietary Supplements [VITAL (Vitamins and Lifestyle study cohort)]; R01 CA39742 (Iowa Women's Health Study); CA164973 (Multiethnic Cohort); UM1 CA186107, P01 CA87969, UM1 CA176726, and R01 CA67262 (Nurses' Health Study, Nurses' Health Study II); NIH UM1 CA182934 and center grants P30 CA016087 and P30 ES000260 (NYU Women's Health Study); grants from the Swedish Research Council (Swedish Mammography Cohort). All aspects of the Cancer Prevention Study II were funded by the Intramural Research Program of the American Cancer Society and by the NCI Intramural Research Program, Intramural Research Program of the NIH, and National Institute of Environmental Health Sciences. The Sister Study is funded by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences project Z01-ES044005. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sant~e et de la Recherche Medicale (INSERM; France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF; Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Nordforsk (Norway); Health Research Fund (FIS), PI13/00061 to Granada; PI13/01162 to EPICMurcia), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020; Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vasterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPICNorfolk, MR/M012190/1 to EPIC-Oxford; United Kingdom). Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414, and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database.